Cargando…
Phytochemicals and PI3K Inhibitors in Cancer—An Insight
In today's world of modern medicine and novel therapies, cancer still remains to be one of the prime contributor to the death of people worldwide. The modern therapies improve condition of cancer patients and are effective in early stages of cancer but the advanced metastasized stage of cancer...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736021/ https://www.ncbi.nlm.nih.gov/pubmed/29311925 http://dx.doi.org/10.3389/fphar.2017.00916 |
_version_ | 1783287311998386176 |
---|---|
author | Suvarna, Vasanti Murahari, Manikanta Khan, Tabassum Chaubey, Pramila Sangave, Preeti |
author_facet | Suvarna, Vasanti Murahari, Manikanta Khan, Tabassum Chaubey, Pramila Sangave, Preeti |
author_sort | Suvarna, Vasanti |
collection | PubMed |
description | In today's world of modern medicine and novel therapies, cancer still remains to be one of the prime contributor to the death of people worldwide. The modern therapies improve condition of cancer patients and are effective in early stages of cancer but the advanced metastasized stage of cancer remains untreatable. Also most of the cancer therapies are expensive and are associated with adverse side effects. Thus, considering the current status of cancer treatment there is scope to search for efficient therapies which are cost-effective and are associated with lesser and milder side effects. Phytochemicals have been utilized for many decades to prevent and cure various ailments and current evidences indicate use of phytochemicals as an effective treatment for cancer. Hyperactivation of phosphoinositide 3-kinase (PI3K) signaling cascades is a common phenomenon in most types of cancers. Thus, natural substances targeting PI3K pathway can be of great therapeutic potential in the treatment of cancer patients. This chapter summarizes the updated research on plant-derived substances targeting PI3K pathway and the current status of their preclinical studies and clinical trials. |
format | Online Article Text |
id | pubmed-5736021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57360212018-01-08 Phytochemicals and PI3K Inhibitors in Cancer—An Insight Suvarna, Vasanti Murahari, Manikanta Khan, Tabassum Chaubey, Pramila Sangave, Preeti Front Pharmacol Pharmacology In today's world of modern medicine and novel therapies, cancer still remains to be one of the prime contributor to the death of people worldwide. The modern therapies improve condition of cancer patients and are effective in early stages of cancer but the advanced metastasized stage of cancer remains untreatable. Also most of the cancer therapies are expensive and are associated with adverse side effects. Thus, considering the current status of cancer treatment there is scope to search for efficient therapies which are cost-effective and are associated with lesser and milder side effects. Phytochemicals have been utilized for many decades to prevent and cure various ailments and current evidences indicate use of phytochemicals as an effective treatment for cancer. Hyperactivation of phosphoinositide 3-kinase (PI3K) signaling cascades is a common phenomenon in most types of cancers. Thus, natural substances targeting PI3K pathway can be of great therapeutic potential in the treatment of cancer patients. This chapter summarizes the updated research on plant-derived substances targeting PI3K pathway and the current status of their preclinical studies and clinical trials. Frontiers Media S.A. 2017-12-14 /pmc/articles/PMC5736021/ /pubmed/29311925 http://dx.doi.org/10.3389/fphar.2017.00916 Text en Copyright © 2017 Suvarna, Murahari, Khan, Chaubey and Sangave. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Suvarna, Vasanti Murahari, Manikanta Khan, Tabassum Chaubey, Pramila Sangave, Preeti Phytochemicals and PI3K Inhibitors in Cancer—An Insight |
title | Phytochemicals and PI3K Inhibitors in Cancer—An Insight |
title_full | Phytochemicals and PI3K Inhibitors in Cancer—An Insight |
title_fullStr | Phytochemicals and PI3K Inhibitors in Cancer—An Insight |
title_full_unstemmed | Phytochemicals and PI3K Inhibitors in Cancer—An Insight |
title_short | Phytochemicals and PI3K Inhibitors in Cancer—An Insight |
title_sort | phytochemicals and pi3k inhibitors in cancer—an insight |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736021/ https://www.ncbi.nlm.nih.gov/pubmed/29311925 http://dx.doi.org/10.3389/fphar.2017.00916 |
work_keys_str_mv | AT suvarnavasanti phytochemicalsandpi3kinhibitorsincanceraninsight AT muraharimanikanta phytochemicalsandpi3kinhibitorsincanceraninsight AT khantabassum phytochemicalsandpi3kinhibitorsincanceraninsight AT chaubeypramila phytochemicalsandpi3kinhibitorsincanceraninsight AT sangavepreeti phytochemicalsandpi3kinhibitorsincanceraninsight |